On March, 25 is anticipated Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB)’s earnings report, RTT reports. This year’s EPS analyst estimate is anticipated to be $-0.04. That is 0.00 % compareed to $-0.04 EPS for last year. 33.33 % negative EPS growth is what Wall Street’s forecasts after $-0.03 reported EPS previous quarter. MTNB reached $1.359 during the last trading session after $0.069 change.Currently Matinas BioPharma Holdings, Inc. is uptrending after 27.72% change in last March 5, 2018. MTNB has 720,264 shares volume. MTNB outperformed the S&P500 by 23.35%.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections.The company has $152.73 million market cap. The firm develops orally delivered therapeutics based on a proprietary, lipid drug delivery platform called cochleate delivery technology.Last it reported negative earnings. The Company’s lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections.
For more Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) news brought out recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Stockhouse.com or Nasdaq.com. The titles are as follows: “Newly-formed Uranium Trading files for a $58 million IPO – Nasdaq” brought out on October 05, 2018, “Paramount Gold Nevada Announces Exercise of Warrants – Nasdaq” on January 29, 2019, “3 Cheap Stocks Under $3 to Consider Now – Nasdaq” with a publish date: June 14, 2018, “The Madison Square Garden Company And PepsiCo Announce Historic Partnership – Stockhouse” and the last “3 Potential Takeover Targets – Nasdaq” with publication date: June 15, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.